Skip to main content

Advertisement

SpringerLink
Log in

Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery

  • HIV Medicine (CJ Yoon, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Opinion statement

Pre-exposure prophylaxis (PrEP) is an effective and evidence-based HIV prevention option and is recommended for individuals with substantial risk for HIV infection [1]. Randomized controlled trials have demonstrated that daily oral PrEP dramatically reduces the risk of HIV infection when it is taken as directed. Concerns regarding widespread emergence of antiretroviral resistance attributable to PrEP and behavioral disinhibition have to date not been observed in clinical trials and open-label demonstration projects. PrEP has great potential as part of an HIV risk reduction strategy, and barriers to wider implementation including community education, prescriber availability, and elimination of financial barriers should be aggressively pursued. Adherence is critical to PrEP efficacy and has varied across study populations; developing and refining ways of measuring and supporting adherence is essential to the success of PrEP. Evaluation of long-acting medications and alternative formulations for PrEP is underway and may lead to the wider implementation and impact of PrEP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Centers for Disease Control and Prevention, Pre-exposure prophylaxis for the prevention of HIV in the United States—2014 clinical practice guideline. 2014.

  2. Baeten JM et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. The Partners-PrEP study was one of the first large studies of heterosexual discordant couples indicating significant risk reduction with daily oral TDF or TDF/FTC PrEP. Substudies and open-label continuation phase from this study continue to contribute information regarding durability of effect and factors related to adherence.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Choopanya K et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90. This is the largest controlled trial demonstrating the efficacy and feasibility of oral PrEP for IDU in Thailand.

    Article  PubMed  Google Scholar 

  4. Grant RM et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. The iPrEX study was the first large placebo controlled trial to demonstrate risk reductions with PrEP and was conducted in MSM and TGW. Substudies have contributed substantially to information regarding correlates between adherence and protection in this population.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Thigpen MC et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34. The CDC TDF-2 study contributed to available data regarding efficacy of PrEP for prevention of heterosexual HIV transmission.

    Article  CAS  PubMed  Google Scholar 

  6. Food and Drug Administration (2012), Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus. These comprehensive clinical guidelines provide substantial information regarding screening patients for appropriateness of PrEP, laboratory testing, counseling, and follow-up for PrEP prescribers.

  7. Tsai CC et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995;270(5239):1197–9.

    Article  CAS  PubMed  Google Scholar 

  8. Garcia-Lerma JG et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5(2):e28.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Parikh UM et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol. 2009;83(20):10358–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Garcia-Lerma JG et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):14ra4.

    Article  PubMed  Google Scholar 

  11. Subbarao S et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis. 2006;194(7):904–11.

    Article  CAS  PubMed  Google Scholar 

  12. Baeten JM et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014;14(11):1055–64.

    Article  CAS  PubMed  Google Scholar 

  13. Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5(10):563–73.

    Article  CAS  PubMed  Google Scholar 

  14. Young B et al. Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV outpatient study. J Int Assoc Physicians AIDS Care (Chic). 2007;6(3):178–87.

    Article  Google Scholar 

  15. Solomon MM et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Liu AY et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS ONE. 2011;6(8):e23688.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Kasonde M et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS ONE. 2014;9(3):e90111.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Grant RM et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9. This cohort provides important data regarding longitudinal follow-up of individuals receiving PrEP in an open-label study and indicates continued protection from HIV and lack of substantial behavior changes in those receiving PrEP.

    Article  PubMed  Google Scholar 

  19. Liu A et al. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014;11(3):e1001613.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Arnold EA et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE. 2012;7(7):e40603.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Karris MY et al. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58(5):704–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Liegler T et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014;210(8):1217–27.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Lehman DA, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis.

  24. Grant RM et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. . 2014.

  25. Parikh UM, Mellors JW. HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis. Clin Infect Dis. 2012;55(2):303–4. author reply 304.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Mugwanya KK et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13(12):1021–8.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Marcus JL et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS ONE. 2013;8(12):e81997.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Golub SA et al. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59 Suppl 1:S55–60.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Dai JY et al. Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration. Am J Epidemiol. 2013;177(3):256–63.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Marrazzo JM, Ramjee G, et al. Tenofovir-based pre-exposure prophylaxis for HIV infection among African women.  New Engl J Med. 2015;372:509–18.

  32. Van D. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22. The FEM-PrEP study, together with the VOICE study (see #31, above) provide information regarding the importance of adherence to efficacy of PrEP; both failed to demonstrate risk reduction in the active arms, with low adherence across intervention arms.

    Article  Google Scholar 

  33. Anderson PL et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125. This study used pharmacokinetic data from the STRAND study as well as clinical and drug level information from iPrEX to estimate protection from HIV with various levels of adherence.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Castillo-Mancilla, J.R., et al., Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses, 2014.

  35. Castillo-Mancilla JR et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retrovir. 2013;29(2):384–90.

    PubMed Central  CAS  PubMed  Google Scholar 

  36. Zheng JH et al. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal. 2014;88:144–51.

    Article  CAS  PubMed  Google Scholar 

  37. Liu AY et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS ONE. 2014;9(1):e83736.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Amico KR. Adherence to preexposure chemoprophylaxis: the behavioral bridge from efficacy to effectiveness. Curr Opin HIV AIDS. 2012;7(6):542–8. This review addresses adherence measures, known adherence factors, and suggested interventions to support adherence.

    Article  PubMed  Google Scholar 

  39. Amico KR et al. Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment. AIDS Behav. 2012;16(5):1243–59.

    Article  Google Scholar 

  40. Gilmore HJ et al. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDS. 2013;27(10):560–6.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Corneli AL et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2014;66(3):324–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Golub SA et al. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013;27(4):248–54.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Baeten JM et al. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S122–9.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Ware NC et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr. 2012;59(5):463–8.

    Article  CAS  PubMed  Google Scholar 

  45. Haberer JE et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10(9):e1001511.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Corneli A et al. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. J Acquir Immune Defic Syndr. 2014;67(5):555–63.

    Article  CAS  PubMed  Google Scholar 

  47. Corneli AL et al. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. J Int AIDS Soc. 2014;17(3 Suppl 2):19152.

    PubMed Central  PubMed  Google Scholar 

  48. van der Straten A et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(3 Suppl 2):19146.

    PubMed Central  PubMed  Google Scholar 

  49. MRC Clinical Trials Unit. PROUD study interim analysis finds pre-exposure prophylaxis (PrEP) is highly protective against HIV for gay men and other men who have sex with men in the UK. 2014 10/16/14 1/25/15]; Available from: http://www.proud.mrc.ac.uk/pdf/PROUD Statement 161014.pdf.

  50. Kirby T, Thornber-Dunwell M. Uptake of PrEP for HIV slow among MSM. Lancet. 2014;383(9915):399–400.

    Article  PubMed  Google Scholar 

  51. Flash C et al. Two years of Truvada for pre-exposure prophylaxis utilization in the US. J Int AIDS Soc. 2014;17(4 Suppl 3):19730.

    PubMed Central  PubMed  Google Scholar 

  52. Cohen, S.E., et al., high interest in pre-exposure prophylaxis among men who have sex with men at risk for HIV-infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr, 2014.

  53. Galindo GR et al. Community member perspectives from transgender women and men who have sex with men on pre-exposure prophylaxis as an HIV prevention strategy: implications for implementation. Implement Sci. 2012;7:116.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Tellalian D et al. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS. 2013;27(10):553–9.

    Article  PubMed  Google Scholar 

  55. Tripathi A et al. Preexposure prophylaxis for HIV infection: healthcare providers’ knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J. 2012;105(4):199–206.

    Article  PubMed  Google Scholar 

  56. White JM et al. Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS. 2012;26(7):395–405.

    PubMed Central  PubMed  Google Scholar 

  57. Clinician Consultation Center at UCSF. The CCC Pre-Exposure Prophylaxis Service. 1/25/15]; Available from: http://nccc.ucsf.edu/clinical-resources/pep-resources/prep/.

  58. Project Inform. PrEP/PEP Point-of-Care Cards. 1/25/15]; Available from: http://www.projectinform.org/prep-pep-cards/.

  59. The National LGBT Health Education Center. Taking a history of sexual health: opening the door to effective hiv and sti prevention (webinar). 4/17/14 [cited 2014; Available from: http://www.lgbthealtheducation.org/training/online-courses/neaetc2014/.

  60. Johns Hopkins Institute for Clinical and Translational Research. HIV pre-exposure prophylaxis (PrEP) risk assessment tool: individual risk calculator. 1/25/15]; Available from: https://ictrweb.johnshopkins.edu/ictr/utility/prep.cfm.

  61. Gilead Sciences Inc. Truvada for a pre-exposure prophylaxis indication: risk evaluation and mitigation strategy (REMS). 1/25/15]; Available from: http://www.truvadapreprems.com/.

  62. King HL et al. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav. 2014;18(9):1722–5.

    Article  PubMed  Google Scholar 

  63. My PrEP Experience. Truvada track—monitoring insurance and Medicaid coverage of Truvada for PrEP. 1/27/15]; Available from: http://myprepexperience.blogspot.com/p/truvada-track.html.

  64. Project Inform. How to choose a health plan in covered California. 12/18/14; Available from: http://www.projectinform.org/pdf/CCguide.pdf.

  65. Washington State Department of Health. Pre-exposure prophylaxis drug assistance program (PrEP DAP). 1/27/15]; Available from: http://www.doh.wa.gov/YouandYourFamily/IllnessandDisease/HIVAIDS/HIVCareClientServices/PrEPDAP.

  66. Gilead Sciences Inc. Truvada for PrEP medication assistance program. 1/27/15]; Available from: http://www.gilead.com/responsibility/us-patient-access/truvada for prep medication assistance program.

  67. Sionean C et al. HIV risk, prevention, and testing behaviors among heterosexuals at increased risk for HIV infection—national HIV behavioral surveillance system, 21 U.S. cities, 2010. MMWR Surveill Summ. 2014;63(14):1–39.

    PubMed  Google Scholar 

  68. Finlayson TJ et al. IV risk, prevention, and testing behaviors among men who have sex with men—national HIV behavioral surveillance system, 21 U.S. cities, United States, 2008. MMWR Surveill Summ. 2011;60(14):1–34.

    PubMed  Google Scholar 

  69. Broz D et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users—national HIV behavioral surveillance system, 20 U.S. cities, 2009. MMWR Surveill Summ. 2014;63(6):1–51.

    PubMed  Google Scholar 

  70. United States Presidential Commission on HIV/AIDS, National HIV/AIDS strategy for the United States, 2010, White House Office of National AIDS Policy.

  71. Un médicament pris au moment des rapports sexuels réduit efficacement le risque d’infection. 01/05/15]; Available from: http://www.ipergay.fr/un-grand-succes-dans-la-lutte-contre-le-vih-sida.html.

  72. Fonsart JCC, Spire B, Molina J-M. High adherence rate to intermittent oral PrEP with TDF/FTC among high risk MSM (ANRS IPERGAY). Melbourne: 20th International AIDS Conference (AIDS 2014); 2014.

    Google Scholar 

  73. Kibengo FM et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS ONE. 2013;8(9):e74314.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Mutua G et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS ONE. 2012;7(4):e33103.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Winner B et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.

    Article  CAS  PubMed  Google Scholar 

  76. Eisingerich AB et al. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS ONE. 2012;7(1):e28238.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Meyers K et al. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS ONE. 2014;9(12):e114700.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Wheelock A et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS ONE. 2013;8(1):e54288.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Andrews CD et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Study to evaluate the safety tolerability and acceptability of long acting injections of the human immunodeficiency virus (HIV) integrase inhibitor, GSK1265744, in HIV uninfected men (ECLAIR). 01/05/2015]; Available from: http://www.clinicaltrials.gov/ct2/show/NCT02076178.

  81. Spreen WR, Margolis DA, Pottage Jr JC. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013;8(6):565–71.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. HPTN 076: phase II safety and acceptability of an investigational injectable product, TMC278 LA, for pre exposure prophylaxis (PrEP). 01/05/15]; Available from: http://www.hptn.org/research_studies/hptn076.asp.

  83. Devlin B et al. Development of dapivirine vaginal ring for HIV prevention. Antivir Res. 2013;100(Suppl):S3–8.

    Article  CAS  PubMed  Google Scholar 

  84. Boffito M et al. New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. Drugs. 2014;74(1):7–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Gilead Sciences donated a study drug to the US PrEP demo project, of which Liu is the protocol chair, Susanne Doblecki-Lewis is a co-investigator and site medical director, and Stephanie Cohen is a site co-PI.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

    Susanne Doblecki-Lewis MD

  2. Population Health Division, San Francisco Department of Health, San Francisco, CA, USA

    Stephanie Cohen MD, MPH

  3. Bridge HIV, San Francisco Department of Health, 25 Van Ness Avenue, Suite 100, San Francisco, CA, 94102, USA

    Albert Liu MD, MPH

  4. Division of Infectious Diseases, University of California, San Francisco, CA, USA

    Stephanie Cohen MD, MPH & Albert Liu MD, MPH

Authors
  1. Susanne Doblecki-Lewis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephanie Cohen MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Albert Liu MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert Liu MD, MPH.

Additional information

This article is part of the Topical Collection on HIV Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Doblecki-Lewis, S., Cohen, S. & Liu, A. Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery. Curr Treat Options Infect Dis 7, 101–112 (2015). https://doi.org/10.1007/s40506-015-0046-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-015-0046-4

Keywords

Search

Navigation